Expert review outlines technical barriers and solutions for ctDNA monitoring in large B-cell lymphoma, suggesting multi-marker tumor-informed assays optimize sensitivity.
Diffuse Large B-cell lymphoma is an aggressive lymphoma in which management is constrained by incomplete molecular characterization and the absence of sensitive markers of treatment response. Cell-free DNA offers a noninvasive approach for tumor genotyping and minimal residual disease monitoring. Nevertheless, technical challenges persist, including low cfDNA abundance and the discrimination of low allele fraction variants from background noise. Tumor-informed assays tracking multiple genetic markers substantially improve sensitivity of disease monitoring. Standardization and prospective validation will facilitate routine clinical implementation.
No takes yet. Share an insight, caveat, or question.
Krupka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: